New blood test offers early detection of drug-induced tissue damage in cancer patients
A team of researchers have applied a novel blood test that can detect early signs of potentially fatal lung damage in cancer ...
Health on MSN1y
What Is Enhertu (Fam-Yrastuzumab Deruxtecan-Nxki)?
Fact checked by Marley Hall Medically reviewed by Marla Anderson, MD The Food and Drug Administration (FDA) granted priority review for Enhertu (fam-trastuzumab deruxtecan-nxki) in 2024. This drug ...
News Medical1d
New blood test detects early lung damage in cancer patients on targeted therapy
ADCs, including the widely used cancer drug Enhertu (trastuzumab deruxtecan), represent a new wave of targeted therapies.
pharmaphorum2y
FDA gives Daiichi Sankyo's HER3 drug a breakthrough tag
AZ has already licensed rights to HER2-targeting drug Enhertu (trastuzumab deruxtecan) – which is already on the market for HER2-positive breast and gastric cancers – as well as ...
BioWorld5d
First-in-class dual-payload anti-HER2 agent presented
Anti-HER2 antibody-drug conjugates (ADCs) have proven effective in multiple tumor types. However, between 64% and 85% of HER2+ breast and gastric cancer patients retain HER2 expression after treatment ...
pharmaphorum7d
Seagen wins Enhertu patent dispute with Daiichi Sankyo
Seagen claims Enhertu (trastuzumab deruxtecan) – an antibody-drug conjugate (ADC) targeting HER2 – infringes a patient it holds (No. 10,808,039) covering ADCs that include auristatin compounds ...
La Razón Digital7d
Ya está disponible trastuzumab deruxtecán contra el cáncer de mama metastásico HER2-low en todas las autonomías
La investigación continúa. De hecho, como ha demostrado el estudio "Destiny Breast 06", presentado este año, trastuzumab-deruxtecan mejora resultados en cáncer de mama metastásico en ...
Medscape4d
HER2 Overexpression/Amplification and Trastuzumab Treatment in Advanced Ovarian Cancer: A GINECO Phase II Study
Trastuzumab, tested only as a single agent, has been shown to achieve 7% response in heavily pretreated patients with AOC with 3+ and 2+ HER2 immunostaining by immunohistochemistry (IHC).
Medscape13d
Trastuzumab Duocarmazine Ups PFS, Ocular Toxicity in Advanced HER2+ Breast Cancer
Additionally, the study did not establish the efficacy of T-Duo in patients previously treated with trastuzumab deruxtecan. This study was supported by Byondis B.V. Co-authors Evelyn van den Tweel ...
Redacción Médica2y
Trastuzumab deruxtecán recibe la designación de terapia innovadora en EEUU
En el estudio, trastuzumab deruxtecan demostró una mejora clínica y estadísticamente significativa, tanto en supervivencia libre de progresión (SLP) como en supervivencia global (SG ...
Business Wire14d
Three Phase 3 Trials of Datopotamab Deruxtecan-Based Combinations Initiated in Patients with Advanced Nonsquamous Non-Small Cell Lung Cancer
TOKYO & BASKING RIDGE, N.J.--(BUSINESS WIRE)--The first patients have been dosed in three global, randomized phase 3 trials evaluating the efficacy and safety of datopotamab deruxtecan (Dato-DXd ...
National Institute for Health and Care Excellence1mon
Awaiting development: Guidance and quality standards
Tolebrutinib for treating relapsing multiple sclerosis TS ID 11845 Technology appraisal guidance Toripalimab with chemotherapy for treating advanced oesophageal squamous cell cancer without previous ...